



Translation

Notice: This document is a translation of the original Japanese document and is for reference purposes only. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

Alfresa Holdings Corporation
May 18, 2026

Notice on the Decision of Terms of the 1st Issuance of Stock Acquisition Right via Third-Party Allotment for Acquisition of Own Shares via Fully Committed Share Repurchase (Japanese ASR)

Alfresa Holdings Corporation (the “Company”) hereby announces that as a result of the purchase of treasury shares through Tokyo Stock Exchange (“TSE”) off-auction own share repurchase trading system (ToSTNeT-3), terms have been decided for the 1st issuance of stock acquisition right via third-party allotment as resolved at the Board of Directors meeting on May 15, 2026. For details, please refer to the Company’s press release entitled “Notice Regarding Acquisition of Own Shares and Acquisition of Own Shares through the Off-Auction Own Share Repurchase Trading System (ToSTNeT-3)(Acquisition of Own Shares Pursuant to Article 459, Paragraph 1 of the Companies Act and Provisions of the Articles of Incorporation and Acquisition of Own Shares through Fully Committed Share Repurchase (Japanese ASR))” dated May 15, 2026.

1. Overview of the terms

(1) Exercisable shares	Exercisable shares: 2,208,100 shares (maximum) * *The maximum number of exercisable shares is based on the assumption that the number of shares acquired at average price in (2) below is zero.
(2) Number of Exercisable shares	Number of Exercisable shares = (i) Number of shares acquired – (ii) Number of shares acquired at average price (i) The Number of shares acquired is 2,208,100 shares (ii) The Number of shares acquired at average price is calculated as follows $\text{Number of shares acquired at average price} = \frac{\text{① Repurchase amount}}{\text{② Average price}}$

Note: This press release does not constitute an offer of any securities for sale. This press release has been prepared for the purpose of publicly announcing the repurchase of our own stock and allotment of our stock acquisition rights to a specific third party and not for the purpose of soliciting investment or engaging in any other similar activities. This press release is not an offer of securities for sale in the United States. The securities referred herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States.

	<ul style="list-style-type: none"> ① Repurchase amount is 5,250,861,800 yen ② The average price is calculated by multiplying the average VWAP (arithmetic mean of the VWAP of ordinary trades of the Company's common shares displayed on 2784_JT Equity AQR screen (or any substitute screen or service) released by Bloomberg L.P. on each trading day during the period for calculating the average share price) by 99.973%. The period for calculating the average share price shall be the period from May 19, 2026 to the day before the date of exercising the stock acquisition right.
--	--

About the Alfresa Group

The Alfresa Group is a leader in the Japanese healthcare industry and is dedicated to making its corporate philosophy, “we create and deliver a fresh life for all,” come true through a wide range of business lines, including ethical pharmaceuticals wholesaling, OTC pharmaceuticals wholesaling, pharmaceutical manufacturing, operating dispensing pharmacies, regenerative medicine-related business, and CRO business. Alfresa Holdings Corporation (TSE:2784) reported consolidated revenue of ¥3.1 trillion for the fiscal year ended March 31, 2026. For more information, please see: <https://www.alfresa.com/eng/>

Note: This press release does not constitute an offer of any securities for sale. This press release has been prepared for the purpose of publicly announcing the repurchase of our own stock and allotment of our stock acquisition rights to a specific third party and not for the purpose of soliciting investment or engaging in any other similar activities. This press release is not an offer of securities for sale in the United States. The securities referred herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States.